. Author manuscript; available in PMC: 2020 Apr 10.

Published in final edited form as: Hematol Oncol Clin North Am. 2019 Feb;33(1):103–120. doi: 10.1016/j.hoc.2018.09.001

Table 8.

Systemic therapies used to treat mycosis fungoides/Sézary syndrome

Systemic Therapies	Overall Response Rate
Bexarotene	ORR 45%, CR 13%¹⁴
IFN a	ORR 64%; CR 27% in stage IA–IVA¹⁵
Romidepsin	ORR 38%, CR 6%¹⁶
Methotrexate	ORR 58%, CR 41% in erythrodermic MF¹⁷ ORR 33%, CR 12% in plaque-stage MF¹⁸
Brentuximab vedotin	ORR 65%, CR 10%¹⁰
Pralatrexate	ORR 41%, CR <1%¹⁹
Doxorubicin	ORR 30% to 80%, CR 20% to 60%^20,21
Gemcitabine	ORR 51.0%–70.5%, CR 11.5%–23.0%^22,23
Pembrolizumab	ORR 38%, 1 CR²⁴
Bortezomib	ORR 67%, CR 17%²⁵

Abbreviations: IFN, interferon; ORR, overall response rate.